This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderson, P. M. Articles by Rahman, E. Search for Related Content PubMed PubMed Citation Articles by Anderson, P. M. Articles by Rahman, E.

Aerosol Granulocyte Macrophage-Colony Stimulating Factor: A Low Toxicity, Lung-specific Biological Therapy in Patients with Lung Metastases¹

Departments of Pediatrics [P. M. A., M. L. C., M. W., C. A. S. A., W. A. S.] and Oncology [S. N. M., J. A. S., P. B., M. G., E. R.], Mayo Clinic, Rochester Minnesota 55905

The objective was to study the feasibility of granulocyte macrophage-colony stimulating factor (GM-CSF) delivery to the lung using an aerosol in humans. A Phase I dose escalation study provided GM-CSF at three dose levels as a twice-a-day (BID) x 7 days schedule. Pulmonary functions were monitored using a remote spirometry device. Blood counts were checked at the beginning and end of each week of GM-CSF nebulization. If no toxicity was encountered, patients rested for 7 days and then were treated at the next dose level. Six of seven patients were successfully dose escalated from 60 µg/dose BID x 7 days, to 120 µg/dose BID x 7 days, then 240 µg/dose BID x 7 days. No toxicity was seen. Comparison of day 0 and day 7 blood leukocyte counts showed no significant increases in either leukocyte numbers or percentage of neutrophils. Pulmonary functions test changes were minor. No significant change in forced vital capacity, FEV1, peak flow, or FEF 25-75 related to either time or dose level was observed. One patient’s lung metastases progressed. The other five patients received an additional 2–6 months of intermittent aerosol GM-CSF at dose level 3 without side effects. One patient with Ewing’s sarcoma has a complete response, and a patient with melanoma had a partial response; the other three had stabilization of pulmonary metastases for 2–6 months. Aerosol delivery of GM-CSF is feasible, safe, and possibly effective. Aerosol cytokine delivery may achieve effective immunological activation against cancer in the lung and is worthy of further study.

This article has been cited by other articles:

				G. Quezada, N. V. Koshkina, P. Zweidler-McKay, Z. Zhou, D. P. Kontoyiannis, and E. S. Kleinerman Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis Antimicrob. Agents Chemother., February 1, 2008; 52(2): 716 - 718. [Abstract] [Full Text] [PDF]

				Y. Zou, C. Tornos, X. Qiu, M. Lia, and R. Perez-Soler p53 Aerosol Formulation with Low Toxicity and High Efficiency for Early Lung Cancer Treatment Clin. Cancer Res., August 15, 2007; 13(16): 4900 - 4908. [Abstract] [Full Text] [PDF]

				B. P.H. Wittgen, P. W.A. Kunst, K. van der Born, A. W. van Wijk, W. Perkins, F. G. Pilkiewicz, R. Perez-Soler, S. Nicholson, G. J. Peters, and P. E. Postmus Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung Clin. Cancer Res., April 15, 2007; 13(8): 2414 - 2421. [Abstract] [Full Text] [PDF]

				O C Ioachimescu and M S Kavuru Pulmonary alveolar proteinosis Chronic Respiratory Disease, July 1, 2006; 3(3): 149 - 159. [Abstract] [PDF]

				M. E. Wylam, R. Ten, U. B. S. Prakash, H. F. Nadrous, M. L. Clawson, and P. M. Anderson Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur. Respir. J., March 1, 2006; 27(3): 585 - 593. [Abstract] [Full Text] [PDF]

				R. Tazawa, E. Hamano, T. Arai, H. Ohta, O. Ishimoto, K. Uchida, M. Watanabe, J. Saito, M. Takeshita, Y. Hirabayashi, et al. Granulocyte-Macrophage Colony-Stimulating Factor and Lung Immunity in Pulmonary Alveolar Proteinosis Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1142 - 1149. [Abstract] [Full Text] [PDF]

				R. Gorlick, P. Anderson, I. Andrulis, C. Arndt, G. P. Beardsley, M. Bernstein, J. Bridge, N.-K. Cheung, J. S. Dome, D. Ebb, et al. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary Clin. Cancer Res., November 15, 2003; 9(15): 5442 - 5453. [Abstract] [Full Text] [PDF]

				K. Shingu, C. Kruschinski, A. Luhrmann, K. Grote, T. Tschernig, S. von Horsten, and R. Pabst Intratracheal Macrophage-Activating Lipopeptide-2 Reduces Metastasis in the Rat Lung Am. J. Respir. Cell Mol. Biol., March 1, 2003; 28(3): 316 - 321. [Abstract] [Full Text] [PDF]

				J. F. Seymour and J. J. Presneill Pulmonary Alveolar Proteinosis: Progress in the First 44 Years Am. J. Respir. Crit. Care Med., July 15, 2002; 166(2): 215 - 235. [Abstract] [Full Text] [PDF]

				M. Santosuosso, M. Divangahi, A. Zganiacz, and Z. Xing Reduced tissue macrophage population in the lung by anticancer agent cyclophosphamide: restoration by local granulocyte macrophage-colony-stimulating factor gene transfer Blood, February 15, 2002; 99(4): 1246 - 1252. [Abstract] [Full Text] [PDF]

				S. A. Bouwhuis, S. N. Markovic, M. T. McEvoy, and M. R. Pittelkow Extracorporeal Photopheresis and Adjuvant Aerosolized Granulocyte-Macrophage Colony-Stimulating Factor for Sezary Syndrome Mayo Clin. Proc., February 1, 2002; 77(2): 197 - 200. [Abstract] [PDF]

				S. Sharma, D. White, A. R. Imondi, M. E. Placke, D. M. Vail, and M. G. Kris Development of Inhalational Agents for Oncologic Use J. Clin. Oncol., March 15, 2001; 19(6): 1839 - 1847. [Abstract] [Full Text] [PDF]

				J. F. SEYMOUR, J. J. PRESNEILL, O. D. SCHOCH, G. H. DOWNIE, P. E. MOORE, I. R. DOYLE, J. M. VINCENT, K. NAKATA, T. KITAMURA, D. LANGTON, et al. Therapeutic Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Idiopathic Acquired Alveolar Proteinosis Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 524 - 531. [Abstract] [Full Text]

				D. Lawson and J. M. Kirkwood Granulocyte-Macrophage Colony-Stimulating Factor: Another Cytokine With Adjuvant Therapeutic Benefit in Melanoma? J. Clin. Oncol., April 1, 2000; 18(8): 1603 - 1605. [Full Text] [PDF]